Biotech IPO Gains Crush AI Listings With Standout 55% Return
(Bloomberg) — The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.
US initial public offerings of biotech and pharmaceutical companies this year have produced a weighted average return of 55%, according to data compiled by Bloomberg.
